This year, Cystic Fibrosis Advocates inspired new champions in Washington, D.C. and in state capitols across the country to take action on critical CF-related issues.
The New England Journal of Medicine, the world's most influential and widely read medical periodical, features a study this week about a Phase 2 clinical trial of VX-770, an oral drug in development that targets the root cause of cystic fibrosis.
A key focus of this year's North American Cystic Fibrosis Conference (NACFC) was the progress of the more than 30 potential new therapies moving through the CF Foundation's drug development pipeline.
Academy Award-Winning Movie Director and Oklahoma Native Join the Cystic Fibrosis Foundation to Fight Fatal Disease
Legislation to Help Speed Research for Cystic Fibrosis and Other Rare Diseases
This month, 15-year-old Molly Bonnell and her sister Emily, 13, who have cystic fibrosis, discovered how easy it is to make their voices heard in Congress -- without leaving their living room.
Historic Time in Treatment of Rare Disease as Promising Drugs Reach Phase 3 Trials